Advertisement

Breast Cancer Research and Treatment

, Volume 134, Issue 2, pp 895–897 | Cite as

High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?

  • Miriam J. Smith
  • Franchesca L. Gifford
  • Fiona Lalloo
  • William G. Newman
  • D. Gareth R. Evans
Letter to the Editor

To the editor,

Recently, two genes RAD51C [1] and RAD51D [2] have been identified as high-risk ovarian cancer genes. However, their contribution to breast cancer risk is less clear [2]. Indeed a recent analysis of both genes in the familial breast cancer study (FBCS) cohort has not suggested any increased risk of breast cancer, but a 6–8 fold increase in ovarian cancer risk for both genes [3]. We show here that the contribution of RAD51C and RAD51D gene mutations to an inherited high risk of ovarian cancer is very small.

Until the discovery of pathogenic mutations in RAD51C and RAD51D, it was assumed that the majority, if not all, of the inherited breast and ovarian cancer was due to mutations in BRCA1 or BRCA2 [4]. Ninety-five percent of families with the breast cancer linkage consortium (BCLC) criteria of at least four breast or ovarian cancers with the breast cancers diagnosed <60 years of age and at least one ovarian cancer in the family were predicted to have a mutation in either...

Keywords

Breast Cancer Ovarian Cancer Ovarian Cancer Risk High Risk Family Ovarian Cancer Family 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

D. G. E., W. G. N. and F. L. are supported by the NIHR Biomedical Research Centre, Manchester. Additional grant support was from The Genesis Breast Cancer Prevention Appeal. We would also like to thank Prof Nazneen Rahman and her team at ICR for supplying us with the RAD51D results and contributing towards RAD51C testing.

Disclosures

None.

References

  1. 1.
    Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Müller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5):410–414PubMedCrossRefGoogle Scholar
  2. 2.
    Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, Rogers MT, Shanley S, Walker L, Breast Cancer Susceptibility Collaboration (UK), Eccles D, Evans DG, Renwick A, Seal S, Lord CJ, Ashworth A, Reis-Filho JS, Antoniou AC, Rahman N (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 43(9):879–882. doi: 10.1038/ng.893 PubMedCrossRefGoogle Scholar
  3. 3.
    Loveday C, Turnbull C, Ruark E, Xicola R, Ramsay E, Hughes D, Warren- Perry M, Snape K, Breast Cancer Susceptibility Collaboration (UK), Eccles D, Evans DG, Renwick A, Renwick A, Seal S, Reis-Filho JS, Antoniou AC, Rahman N (2012) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 44(5):475–476Google Scholar
  4. 4.
    Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BAJ, Gayther SA, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott RJ, Maugard CM, Vasen H, Seitz S, Cannon-Albright LA, Schofield A, Zelada-Hedman M and The Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62(3):676–689Google Scholar
  5. 5.
    Evans DG, Lalloo F, Cramer A, Jones E, Knox F, Amir E, Howell A (2009) Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 46(12):811–817PubMedCrossRefGoogle Scholar
  6. 6.
    Evans DGR, Young K, Bulman M, Shenton A, Lalloo F (2008) Mutation testing for BRCA1/2 in ovarian cancer families: use of histology to predict status. Clin Genet 73(4):338–345PubMedCrossRefGoogle Scholar
  7. 7.
    Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, Iddenden I, Woodward E, Lalloo F, Rahman N, Maher ER, Evans DGR (2007) The trouble with phenocopies: are those testing negative for a family BRCA1/2 mutation really at population risk? J Med Genet 44(1):10–15PubMedCrossRefGoogle Scholar
  8. 8.
    Gerhardus A, Schleberger H, Schlegelberger B, Gadzicki D (2007) Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review. Eur J Hum Genet 15(6):619–627PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2012

Authors and Affiliations

  • Miriam J. Smith
    • 1
  • Franchesca L. Gifford
    • 1
  • Fiona Lalloo
    • 1
  • William G. Newman
    • 1
  • D. Gareth R. Evans
    • 1
  1. 1.Department of Genetic Medicine, Manchester Academic Health Science CentreCentral Manchester Foundation Trust, The University of ManchesterManchesterUK

Personalised recommendations